RNA activation (RNAa), mediated by small activating RNAs (saRNAs), upregulates endogenous gene expression through recruitment of the Argonaute proteins to the promoter, natural antisense transcripts, or other noncoding RNAs. This mechanistically distinct modality addresses an unmet need, as few RNA therapeutics current...
Petra Sušjan-Leite, Peter Pečan, Ana Godeša et al.· Molecules· 0 citations
Extracellular vesicles (EVs), particles released from cells, have the potential to become an important in vivo delivery vehicle for CRISPR machinery. Unlike viral vectors such as Adeno-associated virus (AAV), EVs reduce risks associated with immunogenicity, long-term expression, and potential off-target effects. EVs ca...
Peter Pečan, Mateja Manček-Keber· Methods in molecular biology· 0 citations
A unifying innate-sensing architecture for nucleic-acid therapeutics is defined and it is established that reactogenicity is not required for effective vaccination or gene delivery, enabling a broadly applicable strategy to widen the safety window of mRNA medicines, viral vectors, and in vivo genome editing.
D. Lainšček, Š. Malenšek, V. Forstnerič et al.· Molecular Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
